Pharmacy Ipamorelin

SOURCES

Ipamorelin References

Every quantitative claim on this site traces to one of these studies. PubMed and DOI links for each.

Back to the researchRead the FAQ

How this list is used

This is the complete reference list for the Ipamorelin digest. Each numbered entry corresponds to the bracketed citations throughout the site, so any figure — the ~2-hour half-life, the swine ED50, the failed-trial p-value — can be traced to its source. The list leans on the small body of human ipamorelin data (the PK/PD study and the single Phase 2 trial) and the broader preclinical and class-level literature that frames the mechanism and safety. Links go to PubMed or the DOI of record.

  1. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. ↗
  2. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. ↗
  3. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. ↗
  4. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. ↗
  5. Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiol Behav. 2024;284:114644. ↗
  6. Stokes AH, Falls JG, Yoon L, Cariello N, Faiola B, Colton HM, Jordan HL, Berridge BR. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist. Int J Toxicol. 2015;34(2):151-161. ↗
  7. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. ↗
  8. Johansen PB, et al. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Exp Diabesity Res. 2003;4(2):73-81. ↗
  9. Bercu BB, et al. Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone. Endocrinology. 1992;130(5):2579-2586. ↗
  10. Hansen BS, et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999;141(2):180-189. ↗
  11. Hansen TK, et al. Novel orally active growth hormone secretagogues. J Med Chem. 1998;41(19):3705-3714. ↗
  12. Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026 (Epub ahead of print). ↗
  13. Bowers CY, et al. GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab. 1996;9 Suppl 3:261-270. ↗
  14. Massoud AF, et al. Interaction of the growth hormone releasing peptide hexarelin with somatostatin. Clin Endocrinol (Oxf). 1997;47(5):537-547. ↗